Bactroban

(Mupirocin)

ApprovedSmall molecule

Mupirocin is an antibiotic used to treat bacterial skin infections, including impetigo. It works by fighting bacteria but does not work against fungal or viral infections.[2] Bactroban is currently approved and in use across 16 indications[4].[1]

Bactroban is one of 244 small molecule programs targeting Nasal congestion. It is currently in Approved.

Indications

Total Trials

Active Trials

243

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Nasal CongestionActive, not recruiting

Bacterial DiseaseActive, not recruiting

Methicillin-Resistant Staphylococcus AureusCompleted

OsteomyelitisApproved

RadiodermatitisApproved

EpistaxisApproved

Staphylococcus Aureus InfectionActive, not recruiting

SinusitisApproved

Hereditary Hemorrhagic TelangiectasiaApproved

Wound HealingActive, not recruiting

Nasal CongestionApproved

Active, not recruiting

Bacterial DiseaseApproved

Active, not recruiting

Methicillin-Resistant Staphylococcus AureusPreclinical

Completed

OsteomyelitisApproved

Approved

RadiodermatitisApproved

Approved

EpistaxisApproved

Approved

Staphylococcus Aureus InfectionApproved

Active, not recruiting

SinusitisApproved

Approved

Hereditary Hemorrhagic TelangiectasiaApproved

Approved

Wound HealingPreclinical

Active, not recruiting

Showing 10 of 16 indications

Competition

Competitive Landscape

83 competitors in Cesarean Section

#DrugCompanyPhaseTrials

Bactroban

PPadagis LLC

Approved

1 2

Fentanyl-Morphine

SSeoul National University Hospital

Phase 3

2 3

Ondansetron, Dexamethasone

KKing Khaled Eye Specialist Hospital

Phase 3

1 4

Acetaminophen/ibuprofen

SSeoul National University Hospital

Phase 3

1 5

Sebacoyl Dinalbuphine Ester

LLumosa Therapeutics Co., Ltd.

Phase 3

1 6

Morphine - .

RRambam Health Care Campus

Phase 3

1 7

Proamatine

Takeda

Preclinical

1 8

Dynastat

Pfizer

Preclinical

1 9

Duragesic

CCephalon

Preclinical

6 10

Versed

CConrado Roberto Hoffmann Filho

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Colonization4 trials

MRSA Eradication and Decolonization in Children

Terminated·IIndiana University·Phase 4·NCT02127658·14 enrolled

The Natural History of Community-Associated MRSA Infections and Decolonization Strategies

Completed·WWashington University School of Medicine·N/A·NCT00513799·300 enrolled

Bacterial Decolonization Within Dyads

Recruiting·—·N/A·NCT06541145·20 enrolled

Show 1 more trial

S. Aureus Decolonization in HPN Patients.

Terminated·RRadboud University Medical Center·N/A·NCT03173053·63 enrolled

Staphylococcus Aureus3 trials

Mupirocin to Reduce Staphylococcus Aureus Colonization in Infants Hospitalized in a NICU

Completed·—·Phase 2·NCT02967432·216 enrolled

Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment)

Completed·DDestiny Pharma Plc·Phase 4·NCT02284555·12 enrolled

Treatment of Nasal Staphylococcus Aureus Colonization in Patients With HHT

Unknown status·HHospital Italiano de Buenos Aires·Phase 3·NCT02963129·40 enrolled

Staphylococcus aureus infection2 trials

The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis

Completed·NNorthwestern University·Phase 4·NCT00179959·31 enrolled

A Prospective Trial of Nasal Mupirocin, Hexachlorophene Body Wash, and Systemic Antibiotics for Prevention of Recurrent Methicillin Resistant Staphylococcus Aureus Infections

Completed·NNatividad Medical Center·N/A·NCT01049438·31 enrolled

Cystic Fibrosis2 trials

Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)

Terminated·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT01349192·47 enrolled

STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)

Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT03489629·49 enrolled

Prevention1 trial

Use of Ointments in Prevention of Catheter Related Infections in PD

Completed·UUniversity Health Network, Toronto·Phase 4·NCT00400595·200 enrolled

18 more indications

Infection1 trial

Preventing Staphylococcal (Staph) Infection

Completed·UUS Department of Veterans Affairs·Phase 4·NCT00108160·146 enrolled

Impetigo1 trial

Safety and Efficacy of Mupirocin Gel in Children With Impetigo

Completed·RReig Jofre Group·Phase 3·NCT04287777·467 enrolled

Oral Mucositis1 trial

Bacterial Decolonization to Prevent Radiation-induced Oral Mucositis

Unknown status·JJiangxi Provincial Cancer Hospital·Phase 3·NCT05893810·176 enrolled

Methicillin-resistant Staphylococcus Aureus1 trial

An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection in Soldiers

Completed·—·N/A·NCT00289588·3,000 enrolled

Dermatitis1 trial

Bacterial Decolonization to Prevent Radiation Dermatitis

Completed·MMontefiore Medical Center·Phase 2/3·NCT03883828·80 enrolled

Wound Healing1 trial

Efficacy of Hydrocolloid Dressing vs. Topical Antibiotic on Wound Healing of Post-Punch Biopsy Wounds

Completed·UUniversity of Santo Tomas Hospital, Philippines·N/A·NCT07064161·60 enrolled

Cataract1 trial

Prophylaxis Prior to Cataract Surgery Conjunctival Flora and Optimal Ocular Sterilization Technique Prior to Cataract Surgery

Completed·UUniversity of Chicago·N/A·NCT00406913·37 enrolled

Dialysis Patients1 trial

Antimicrobial Photodynamic Therapy in the Nasal Decolonization of Maintenance Hemodialysis Patients

Completed·UUniversity of Nove de Julho·N/A·NCT04047914·34 enrolled

Prophylaxis1 trial

Prophylaxis With Intranasal Mupirocin for Prevention of S. Aureus Infections

Completed·UUniversity Hospital Muenster·Phase 4·NCT00156377·1,200 enrolled

Chronic Rhinosinusitis1 trial

Topical Antibiotics in Chronic Rhinosinusitis

Completed·MMayo Clinic·Phase 1/2·NCT03673956·19 enrolled

Cesarean Section1 trial

Effect of Intranasal Mupirocin on Rate of Staphylococcus Aureus Surgical Site Infection Following Cesarean Sections

Unknown status·HHillel Yaffe Medical Center·N/A·NCT01152593·400 enrolled

Sinus Surgery1 trial

The Use of Antibiotic Sinonasal Rinse After Sinus Surgery

Completed·UUniversity of Miami·Phase 4·NCT02218307·68 enrolled

Surgical Site Infections1 trial

Checklist to Prevent MRSA Surgical Site Infections

Completed·VVA Office of Research and Development·N/A·NCT02216227·1,794 enrolled

MRSA1 trial

MESS-study MRSA Eradication Study Skåne

Completed·RRegion Skane·N/A·NCT01269541·69 enrolled

Peritoneal Dialysis1 trial

Effects of Topical Gentamicin on the Prevention of Peritoneal Dialysis Related Infection

Unknown status·PPhramongkutklao College of Medicine and Hospital·N/A·NCT05251584·60 enrolled

Abscess1 trial

Evaluation of a Staphylococcus Eradication Protocol for Patients Who Present to the ED With Cutaneous Abscess

Completed·TTufts Medical Center·Phase 4·NCT01537783·50 enrolled

Coronary Artery Bypass1 trial

Efficacy Study of Mupirocin on Infection After Coronary Artery Bypass Grafting

Completed·HHorizon Health Network·Phase 3·NCT01949935·974 enrolled

Unspecified3 trials

Monolaurin Ointment Versus Mupirocin Ointment

Completed·VVictoriano Luna Medical Center·Phase 1·NCT06046937·40 enrolled

Pharmacology of Mupirocin in Nasal Application in Healthy Volunteers: Monocentric Study

Active, not recruiting·—·Phase 1·NCT06368856·40 enrolled

Staph Household Intervention for Eradication (SHINE)

Completed·WWashington University School of Medicine·Phase 4·NCT02572791·835 enrolled

Regulatory

FDA Approval Timeline[5]

Dec 31, 1987

BACTROBAN

NDA NDA050591

Sep 18, 1995

BACTROBAN

NDA NDA050703

Dec 11, 1997

BACTROBAN

NDA NDA050746

Dec 4, 2002

CENTANY

NDA NDA050788

Sources

References

[1]
ClinicalTrials.gov — 32 trial records for Mupirocin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Bactroban drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Mupirocin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Mupirocin. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA050788). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Padagis LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Isoleucyl-Trna Synthetase Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: PPadagis LLC

Bactroban

Status by Indication[4][1]

Competitive Landscape

Trials by Indication[1]

Colonization4 trials

Staphylococcus Aureus3 trials

Staphylococcus aureus infection2 trials

Cystic Fibrosis2 trials

Prevention1 trial

Infection1 trial

Impetigo1 trial

Oral Mucositis1 trial

Methicillin-resistant Staphylococcus Aureus1 trial

Dermatitis1 trial

Wound Healing1 trial

Cataract1 trial

Dialysis Patients1 trial

Prophylaxis1 trial

Chronic Rhinosinusitis1 trial

Cesarean Section1 trial

Sinus Surgery1 trial

Surgical Site Infections1 trial

MRSA1 trial

Peritoneal Dialysis1 trial

Abscess1 trial

Coronary Artery Bypass1 trial

Unspecified3 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News